Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
49.6M
-
Number of holders
-
128
-
Total 13F shares, excl. options
-
34.4M
-
Shares change
-
+1.57M
-
Total reported value, excl. options
-
$182M
-
Value change
-
+$11.6M
-
Number of buys
-
62
-
Number of sells
-
-49
-
Price
-
$5.31
Significant Holders of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) as of Q3 2025
144 filings reported holding PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock as of Q3 2025.
PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) has 128 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 34.4M shares
of 49.6M outstanding shares and own 69.24% of the company stock.
Largest 10 shareholders include ACORN CAPITAL ADVISORS, LLC (4.13M shares), VANGUARD GROUP INC (3.69M shares), BlackRock, Inc. (3.58M shares), RENAISSANCE TECHNOLOGIES LLC (2.15M shares), ACADIAN ASSET MANAGEMENT LLC (2.05M shares), AMERICAN CENTURY COMPANIES INC (1.48M shares), DIMENSIONAL FUND ADVISORS LP (1.27M shares), GEODE CAPITAL MANAGEMENT, LLC (984K shares), Russell Investments Group, Ltd. (965K shares), and Connor, Clark & Lunn Investment Management Ltd. (943K shares).
This table shows the top 128 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.